Scientific Article
previous document  unige:11246  next document
add to browser collection

Proteasome blockade exerts an antifibrotic activity by coordinately down-regulating type I collagen and tissue inhibitor of metalloproteinase-1 and up-regulating metalloproteinase-1 production in human dermal fibroblasts

Guerne, P. A.
Published in FASEB Journal. 2006, vol. 20, no. 3, p. 562-564
Abstract Tissue fibrosis results when dysregulation of extracellular matrix (ECM) turnover favors deposition of collagen and other ECM proteins over degradation. Fibrosis may then lead to organ dysfunction and pathology as observed in systemic sclerosis (SSc). In the present study, we investigated the antifibrotic properties of proteasome blockade. A dose- and time-dependent reduction in type-I collagen and tissue inhibitor of metalloproteinase-1 (TIMP-1) production was observed in normal fibroblasts exposed to proteasome inhibitors (PI). In the same culture conditions, metalloproteinase-1 (MMP-1) protein and the collagenolytic activity on type I collagen was increased. The steady-state mRNA levels of COL1A1, TIMP-1, and MMP-1 paralleled protein levels. These effects were dominant over the profibrotic properties of TGF-beta and were observed with fibroblasts generated from normal and SSc skin. PI decreased type I collagen mRNA levels with kinetics similar to those observed with DRB, a specific RNA polymerase II inhibitor, thus indicating transcriptional inhibition. Of interest, PI induced c-Jun phosphorylation and c-Jun nuclear accumulation. The specific N-terminal Jun-kinase inhibitor SP-600125 selectively abrogated c-Jun phosphorylation and, in a dose-dependent fashion, the up-regulated synthesis of MMP-1 induced by PI. Finally, PI did not affect fibroblast viability. Thus, the coordinated down-regulation of collagen and TIMP-1 and up-regulation of MMP-1 renders proteasome blockade an attractive strategy for treating conditions as SSc, characterized by excessive fibrosis.
Keywords Acetylcysteine/ analogs & derivatives/pharmacologyAnthracenes/pharmacologyBoronic Acids/ pharmacologyCollagen Type I/ biosynthesis/geneticsDose-Response Relationship, DrugDown-Regulation/drug effectsExtracellular Matrix/metabolismFibroblasts/ drug effects/metabolismFibrosisGenes, junHumansJNK Mitogen-Activated Protein Kinases/antagonists & inhibitors/metabolismLeupeptins/ pharmacologyMatrix Metalloproteinase 1/ biosynthesis/geneticsPhosphorylation/drug effectsProteasome Endopeptidase Complex/ antagonists & inhibitors/physiologyProtein Processing, Post-Translational/drug effectsProto-Oncogene Proteins c-jun/metabolismPyrazines/ pharmacologyRNA Polymerase II/antagonists & inhibitorsRNA, Messenger/biosynthesis/geneticsScleroderma, Systemic/ metabolismSkin/cytologyTissue Inhibitor of Metalloproteinase-1/ biosynthesis/geneticsTransforming Growth Factor beta/pharmacologyUp-Regulation/drug effects
Stable URL
Full text
Article - document accessible for UNIGE members only Limited access to UNIGE
Other version:
PMID: 16410344
134 hits and 0 download since 2010-08-27
Export document
Format :
Citation style :